2+ channels. In a previous in vitro study, we clarified that efonid- 
, Keiichi IMAGAWA 1) , Noriyuki NAYA 1) , Hajime IWAMA 1) , Satoshi SOMEKAWA 1) , Hiroyuki KAWATA 1) , Manabu HORII 1) , Tamio NAKAJIMA 1) , Shiro UEMURA 1) , and Yoshihiko SAITO 1) Efonidipine can block both L-and T-type Ca 2+ channels. In a previous in vitro study, we clarified that efonid- 
Introduction
Recent molecular biology research has classified Ca 2+ channels into five subtypes-L (long-lasting), T (transient), N (neuronal), P/Q (Purkinje), and R (residual drug-resistant)-according to their localization and function (1, 2) . The L-type Ca 2+ channels are distributed in the cardiac muscle, vascular smooth muscle, and skeletal muscle and are involved in their contraction and relaxation. The N-type Ca 2+ channels are involved in cardiovascular sympathetic nerve activation, and cilnidipine, an antagonist of both L-and T-type Ca 2+ channels, was reported to suppress the occurrence of ischemia/reperfusion arrhythmia (3). The T-type Ca 2+ channels, which were originally called low-voltage-activated channels, are known to be distributed in the sinoatrial node (4) and are involved in pacemaker activity (5) . Furthermore, the T-type Ca 2+ channels regulate vascular tone and hormone secretion (6, 7) . Efonidipine antagonizes both T-and L-type Ca 2+ channels with similar affinity and has little effect on the N-, P/Q-, and R-type Ca 2+ channels. On the other hand, nifedipine and nilvadipine antagonize only the L-type channels and have lit-tle effect on the other types of Ca 2+ channels (8, 9) . Hence, we compared efonidipine, nifedipine and nilvadipine with regard to their characteristic action of T-type Ca 2+ channel antagonism.
Aldosterone plays an important role in the pathophysiology of hypertension, cardiac hypertrophy, and heart failure. Targeting aldosterone synthesis and/or secretion represents a potentially useful approach for the prevention of cardiovascular disease (10) . Aldosterone is synthesized in the zona glomerulosa of the adrenal gland, where it is secreted in a Ca 2+ -dependent manner in response to stimuli such as angiotensin II (Ang II), adrenocorticotropic hormone (ACTH), and increased extracellular K + (11) . Bovine and human glomerulosa cells express L-type and T-type voltage-dependent Ca 2+ channels (12) ; however, recent studies suggest that T-type Ca 2+ channel activity is more closely related to aldosterone production than L-type channel activity (13, 14) .
In a previous in vitro study, we have shown that efonidipine dramatically suppresses aldosterone secretion from human adrenocortical tumor cells (H295R) during Ang II stimulation, whereas nifedipine does not. Further, we confirmed that this action of efonidipine is attributed to the blockade of Ttype Ca 2+ channels (15) . However, there have been few clinical reports on the role of Ca 2+ channel antagonists in reducing plasma aldosterone concentration. The present study was conducted to assess the in vivo effects of efonidipine and nilvadipine on plasma aldosterone concentration.
Methods

Study Design
The present study was approved by the Ethical Committee (No. 311-6) of Nara Medical University. All subjects provided written informed consent to participate in the study.
Five healthy male volunteers (38±7 years) were recruited for the study. None of the volunteers had a history of smoking, and no evidence of previous or current cardiovascular, respiratory, renal, or hepatic disease was obtained from their medical history. None of the volunteers had received medication for at least 1 month before the beginning of the study. This study was a placebo-controlled crossover study with three periods of treatment that were separated by a washout period of at least 7 days. In each subject, three agents were administered in the following order: a placebo sugar tablet, efonidipine (40 mg), and nilvadipine (2 mg). The dosages used in this study were determined as those generally prescribed for patients with hypertension and have been reported to show few side-effects in healthy volunteers (16, 17) . The maximum blood pressure (BP) reduction was attained approximately 6 h after administration of either drug to healthy volunteers. During each period, the drug was administered as a single oral dose at 8:00 AM, and an analysis of its effect was performed before medication (basal state) and 6 h after its administration (posttreatment state). The volunteers were hospitalized from 6:00 AM to 6:00 PM, and were maintained in the supine position in a quiet room. They had fasted from 8:00 PM on the day before the beginning of the study; on the day of the study itself, they did not have breakfast or lunch, and were asked to consume as little water as possible. They were also requested to refrain from consuming alcohol and foods/drinks containing caffeine on the day before the beginning of this study and continuing until the end of the study. We took special care to keep the sampling conditions quiet and stable.
Hemodynamic Analysis
We used an automated sphygmomanometer (HEM-780; Omron Corp, Matsusaka, Japan) to record the pulse rate (PR) and BP. All measurements were obtained with the volunteers in the supine position, after they had evacuated their bladders, in a quiet room.
Neurohormonal Assays
Blood samples were taken in the supine position, immediately after each hemodynamic evaluation time. Plasma renin activity and the Ang II, aldosterone, and ACTH concentrations were measured by radioimmunoassay (RIA) at a contact laboratory (SRL, Inc., Tokyo, Japan). The effect of aldosterone on electrolytes was assessed by routine measurement of electrolytes.
Statistical Analysis
Based on a SD of 5% for plasma aldosterone concentration, the sample size necessary to detect a 10% change in a normal plasma aldosterone concentration was calculated. To decrease the variability among subjects in the control group and in the treatment group, a crossover design was chosen. It was found that a minimum of 6 patients would be required for each group to demonstrate changes of this magnitude. Data are expressed as the mean±SD. One-way analysis of variance (ANOVA) was performed to check for any differences at the basal state between the treatment sequences. A paired t-test was performed to check for any differences between the basal and posttreatment state. A value of p< 0.05 was considered to indicate statistical significance.
Results
The hemodynamic parameters are shown in Table 1 . No significant difference was observed with regard to the systolic BP, diastolic BP, and PR at the basal state between the treatment sequences. All three agents had little effect on BP and PR. The concentrations of ACTH and electrolytes are shown in Table 2 . No significant difference was observed with regard to ACTH and electrolytes at the basal state between the treatment sequences (ACTH: p= 0.41; Na + : p= 0.13; K + : p= 0.43). These three agents had little effect on the concentrations of ACTH and electrolytes. The plasma renin activities at the basal and posttreatment states are shown in Fig. 1 . The plasma renin activity was significantly increased 6 h after the administration of both efonidipine (from 0.78±0.47 to 1.85±0.99 ng/ml/h, p= 0.015) and nilvadipine (from 0.91±0.54 to 1.41±0.70 ng/ml/h, p= 0.0047). The plasma Ang II concentrations are shown in Fig. 2 . The plasma Ang II concentration was significantly increased after the treatment with both efonidipine (from 6.66±3.14 to 10.3±4.76 pg/ml, p= 0.023) and nilvadipine (from 8.16±3.60 to 11.5±4.18 pg/ml, p= 0.042). However, the plasma aldosterone concentration was significantly decreased after efonidipine treatment (from 88.3±21.3 to 81.6±24.9 pg/ml, p= 0.040), but it was increased after nilvadipine treatment (from 66.5±12.2 to 82.17±16.6 pg/ml, p= 0.0049) (Fig. 3) . The placebo did not have any effect on the neurohormonal factors. 
Discussion
The present study was the first to demonstrate that efonidipine, an antagonist of both T-and L-type Ca 2+ channels, was able to decrease the plasma aldosterone concentration despite an increase in plasma renin activity and Ang II concentrations in healthy volunteers, whereas nilvadipine, a dominant L-type Ca 2+ channel antagonist, did not exert such inhibitory effects on the renin-angiotensin-aldosterone system. These findings were consistent with our recent in vitro study, which showed that efonidipine suppresses Ang II-and K + -induced aldosterone secretion from the human adrenocortical tumor cells (H295R), while nifedipine does not. These findings suggest that efonidipine suppresses aldosterone secretion through the blockade of T-type Ca 2+ channels (15) . The present study is also consistent with earlier studies indicating that two other T-type Ca 2+ channel antagonists-mibefradil and tetrandrine-suppress aldosterone secretion from bovine adrenal glomerulosa cells (18, 19) .
Recent clinical studies such as Randomized Aldactone Evaluation Study (RALES) (20) and Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) (21) have shown that suppression of the biological action of aldosterone with a mineralocorticoid receptor (MR) antagonist reduces the incidence of cardiovascular events among patients with severe heart failure. However, MR antagonists trigger life-threatening hyperkalemia in quite a few patients (22) . Patients with cardiovascular disease or renal insufficiency who are treated by combination therapy with an MR antagonist and an angiotensin converting enzyme inhibitor (ACE-I) or an Ang II receptor antagonist should be frequently checked for unexpected increases in serum K + concentration. Efonidipine, which suppresses only the Ang IIand K + -stimulated aldosterone secretion, is likely not to induce such hyperkalemia, suggesting that efonidipine may suppress the action of aldosterone more safely than the MR antagonists.
Many clinical studies have proved that antihypertensive therapy is essential for the treatment of cardiovascular disease (23) (24) (25) , and Ca 2+ channel antagonists, including efonidipine, have the potential to lower the high blood pressure. However, most Ca 2+ channel antagonists stimulate the renin-angiotensin-aldosterone system, and the mechanisms of this stimulation, which are probably multifactorial, are still not completely understood (26) (27) (28) .
The precise correlation between plasma aldosterone concentration and cardiovascular disease is controversial (29) , but with respect to blockade of the renin-angiotensin-aldosterone system, efonidipine, which antagonizes both the T-and L-type Ca 2+ channels, is more useful than other dominant Ltype Ca 2+ channel antagonists in patients with hypertension. The conclusions of this study may be limited by the sampling condition. That is, water and sodium intake were not restricted until the day before the experiments. Stricter control of the salt balance may have minimized the deviation of the results among the three groups of patients.
In conclusion, efonidipine can decrease the plasma aldosterone concentration, despite the increase in the plasma renin activity and Ang II concentrations, which indicates that Ttype calcium channels may also play an essential role in the secretion of aldosterone in healthy human volunteers. 
